Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients' treatment preferences and the impact of both treatments on patient and caregiver quality of life. Materials & methods: Two surveys were conducted (one for adult patients with aHUS and one for caregivers of pediatric patients with aHUS) to quantitatively assess treatment preference and the patient- and caregiver-reported impact of ravulizumab and eculizumab on quality of life. Patients were required to have a diagnosis of aHUS, to be currently receiving treatment with ravulizumab and to have received prior treatment with eculizumab. Participants were recruited via various sources: the Alexion OneSource™ patient support program, the Rare Patient Voice recruitment agency, the aHUS Foundation and directly via a clinician involved in the study. Results: In total, 50 adult patients (mean age: 46.5 years) and 16 caregivers of pediatric patients (mean age: 10.1 years) completed the surveys. Most adult patients (94.0%) and all caregivers reported an overall preference for ravulizumab over eculizumab; infusion frequency was one of the main factors for patients when selecting their preferred treatment. Fewer patients reported disruption to daily life and the ability to go to work/school due to ravulizumab infusion frequency (4.0% and 5.7%, respectively) than eculizumab infusion frequency (72.0% and 60.0%), with similar results for caregivers. Conclusion: Adult patients and caregivers of pediatric patients indicated an overall preference for ravulizumab than eculizumab for the treatment of aHUS, driven primarily by infusion frequency. This study contributes to the emerging real-world evidence on the treatment impact and preference in patients with aHUS.
Tweetable abstract
Surveys of patients and caregivers of pediatric patients with #aHUS showed an overall preference for ravulizumab over eculizumab, driven primarily by infusion frequency. Ravulizumab had a more positive impact on quality of life than eculizumab.
Plain language summary
What is this article about?
Atypical hemolytic uremic syndrome, also called aHUS, is a rare disease that causes kidney damage. Ravulizumab and eculizumab are medications given as intravenous (IV) infusions to treat people who have aHUS. Ravulizumab does not have to be taken as often as eculizumab. In this research, the investigators made surveys to ask people which medication they preferred to treat aHUS and how the medications affected their lives. Those who took part were either adult patients with aHUS, or people who were caring for a child with aHUS. Patients had experience being treated with both ravulizumab and eculizumab.
What were the results?
The survey responses showed that most people preferred ravulizumab over eculizumab. One of the main reasons they preferred ravulizumab was that they did not have to take ravulizumab as often as eculizumab, and their answers showed that this led to less disruption to their daily lives and their work/school attendance.
What do the results mean?
These findings should help doctors, patients and caregivers to decide whether ravulizumab or eculizumab is best for the patient.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 91, 539–551 (2017).
2.
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet 390, 681–696 (2017).
3.
Raina R, Krishnappa V, Blaha T et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther. Apher. Dial. 23, 4–21 (2019).
4.
Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J. Nephrol. 30, 347–362 (2017).
5.
Greenbaum LA, Fila M, Ardissino G et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 89, 701–711 (2016).
• Evidence from this phase 2 study supports the safety and efficacy of eculizumab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).
6.
Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J. Nephrol. 30, 127–134 (2017).
7.
US Food and Drug Administration. Eculizumab (SOLIRIS) prescribing information (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf
8.
US Food and Drug Administration. Approval of eculizumab (SOLIRIS) for the treatment of atypical hemolytic uremic syndrome (aHUS) (2011). https://www.accessdata.fda.gov/drugsatfda_docs/bla/2011/125166Orig1s172-2.pdf
9.
European Medicines Agency. Eculizumab (SOLIRIS) summary of product characteristics (2018). https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf
10.
European Medicines Agency. EU/3/09/653: public summary of positive opinion for orphan designation of eculizumab for the treatment of atypical hemolytic uremic syndrome (aHUS) (2015). https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/09/653-public-summary-positive-opinion-orphan-designation-eculizumab-treatment-atypical-hemolytic_en.pdf
11.
Raina R, Grewal MK, Radhakrishnan Y et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int. J. Nephrol. Renovasc. Dis. 12, 183–204 (2019).
12.
Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169–2181 (2013).
13.
Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of Phase II studies. Kidney Int. 87, 1061–1073 (2015).
14.
Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am. J. Kidney Dis. 68, 84–93 (2016).
• This phase 2 trial demonstrated improvement in hematological, renal and quality of life outcomes in adult patients with aHUS treated with eculizumab.
15.
Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney. Int. Rep. 4, 1568–1576 (2019).
16.
US Food and Drug Administration. Ravulizumab (ULTOMIRIS) prescribing information (2021). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761108s012lbl.pdf
17.
Sheridan D, Yu ZX, Zhang Y et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 13, e0195909 (2018).
18.
Barbour T, Scully M, Ariceta G et al. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney. Int. Rep. 6, 1603–1613 (2021).
19.
Rondeau E, Scully M, Ariceta G et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 97, 1287–1296 (2020).
• A phase 3 study demonstrating the efficacy and safety of ravulizumab in adult patients with aHUS.
20.
Ariceta G, Dixon BP, Kim SH et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 100, 225–237 (2021).
21.
Tanaka K, Adams B, Aris AM et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr. Nephrol. 36, 889–898 (2021).
• An analysis of the safety and efficacy of switching to ravulizumab in a cohort of pediatric patients who were previously treated with eculizumab. Renal and hematological parameters were stable, and there were no unexpected safety concerns.
22.
Tomazos I, Hatswell AJ, Cataland S et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin. Nephrol. 97, 361–372 (2021).
•• An indirect treatment comparison between ravulizumab and eculizumab in patients with aHUS. Findings showed no differences in patient outcomes between treatments.
23.
Dixon BP, Sabus A. Ravulizumab 100 mg/ml formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical hemolytic uremic syndrome. J. Clin. Pharm. Ther. 47, 1081–1087 (2022).
24.
Alexion, AstraZeneca Rare Disease. Alexion receives FDA approval for new advanced formulation of ULTOMIRIS® (ravulizumab-cwvz) with significantly reduced infusion time (2020). https://media.alexion.com/node/22871/pdf
25.
Kimman ML, Rotteveel AH, Wijsenbeek M et al. Development and pretesting of a questionnaire to assess patient experiences and satisfaction with medications (PESaM Questionnaire). Patient. 10, 629–642 (2017).
26.
Williams K, Aggio D, Chen P, Anokhina K, Lloyd AJ, Wang Y. Utility values associated with atypical hemolytic uremic syndrome-related attributes: a discrete choice experiment in five countries. Pharmacoeconomics 39, 901–912 (2021).
27.
Greenbaum LA, Licht C, Nikolaou V et al. Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the Global aHUS Registry. Kidney. Int. Rep. 5, 1161–1171 (2020).
• A longitudinal study of Global aHUS Registry data that showed improvements in patient-reported outcomes, including fatigue, following treatment with eculizumab in patients with aHUS.
28.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. 33, 337–343 (2001).
29.
Bernuy-Guevara C, Chehade H, Muller YD et al. The inhibition of complement system in formal and emerging indications: results from parallel one-stage pairwise and network meta-analyses of clinical trials and real-life data studies. Biomedicines. 8, 355 (2020).
30.
Socie G, Caby-Tosi MP, Marantz JL et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical hemolytic uremic syndrome: 10-year pharmacovigilance analysis. Br. J. Haematol. 185, 297–310 (2019).
• A pharmacovigilance analysis demonstrating the long-term safety of eculizumab in patients with aHUS and paroxysmal nocturnal hemoglobulinuria, using over 28 518 patient-years of data.
31.
Dixon B, Madris-Aris AD, Adams B et al. Two-year efficacy and safety of ravulizumab in adults and children with atypical hemolytic uremic syndrome (aHUS): analysis of two phase 3 studies. Blood 138, 769 (2021).
32.
Wang Y, Johnston K, Popoff E et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J. Med. Econ. 23, 1503–1515 (2020).
33.
Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J. Med. Econ. 25, 1–16 (2022).
•• This study compared the productivity implications of treatment with ravulizumab versus eculizumab for patients with aHUS. Lost productivity costs associated with treatment with ravulizumab were lower than with eculizumab.
34.
Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr. Nephrol. 34, 943–949 (2019).
35.
Laurence J. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. Clin. Adv. Hematol. Oncol. 18, 221–230 (2020).
36.
Chaturvedi S, Dhaliwal N, Hussain S et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood. Adv. 5, 1504–1512 (2021).
37.
Fakhouri F, Fila M, Hummel A et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137, 2438–2449 (2021).
38.
Licht C, Ardissino G, Ariceta G et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 16, 207 (2015).
Information & Authors
Information
Published In
Copyright
© 2023 Becaris Publishing Limited. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 17 March 2023
Accepted: 14 July 2023
Published online: 29 July 2023
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2023-0036
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Dandan Zhang, Yichen Xiao, Hualin Ma, Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review, Frontiers in Pharmacology, 10.3389/fphar.2026.1834141, 17, (2026).
- Ramy Magdy Hanna, Shruti Chaturvedi, Moh-Lim Ong, Arpita Nag, Rui Song, Lynn Huynh, Jordan A. Burdeau, Mei Sheng Duh, Yan Wang, Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study), Kidney Medicine, 10.1016/j.xkme.2025.101198, 8, 2, (101198), (2026).
- Livia Maria Sorrentino, Candida Iacuzzo, Raffaella Sciri, Miriam Zacchia, Mariarosaria Iannuzzi, Paola Marotta, Piercarla Vitale, Chiara Taglioni, Floriana Secondulfo, Daniela Palazzetti, Rocco Baccaro, Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series, Drug Target Insights, 10.33393/dti.2025.3616, 19, 1, (99-107), (2025).
- Jacqueline Young, Gemcitabine-Induced Thrombotic Microangiopathy in a Patient With Metastatic Pancreatic Cancer: A Case Report, Cureus, 10.7759/cureus.95175, (2025).
- Jan Lecouturier, Neil Sheerin, Which Factors Influence Decisions to Withdraw from Eculizumab: A Qualitative Study of Patients Diagnosed with aHUS, The Patient - Patient-Centered Outcomes Research, 10.1007/s40271-025-00771-5, 19, 1, (121-129), (2025).
- Anja Gaeckler, Imad Al‐Dakkak, Nuria Saval, Hans Herman Dieperink, Margriet Eygenraam, Larry A. Greenbaum, Nicole Isbel, Johan Vande Walle, Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis, Clinical Transplantation, 10.1111/ctr.70278, 39, 9, (2025).
- Tanvi Bindal, Aditi Sinha, Arvind Bagga, Eculizumab for Atypical Hemolytic Uremic Syndrome: Guidance for Developing Countries, Indian Journal of Nephrology, 10.25259/IJN_140_2025, 35, (604-613), (2025).
- Shuichi Ito, Hiroshi Hataya, Masanori Matsumoto, Akihiko Shimono, Hirofumi Teranishi, Masaki Okuda, Yoshitaka Miyakawa, Shoichi Maruyama, Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance, Clinical and Experimental Nephrology, 10.1007/s10157-025-02689-6, 29, 11, (1608-1617), (2025).
- Razvan-George Bogdan, Paula Anderco, Cristian Ichim, Anca-Maria Cimpean, Samuel Bogdan Todor, Mihai Glaja-Iliescu, Zorin Petrisor Crainiceanu, Mirela Livia Popa, Atypical Hemolytic Uremic Syndrome: A Review of Complement Dysregulation, Genetic Susceptibility and Multiorgan Involvement, Journal of Clinical Medicine, 10.3390/jcm14072527, 14, 7, (2527), (2025).
- Evi Germeni, Jacie Cooper, Andrew Briggs, Jeffrey Laurence, Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts’ perspectives with associated cost-consequence analysis, BMC Nephrology, 10.1186/s12882-024-03770-0, 25, 1, (2024).
- See more